Express Pharma

US FDA advisers to review Merck’s Molnupiravir soon

The US FDA's panel will meet on 30th November, 2021 to discuss the safety and effectiveness of Molnupiravir for the treatment of mild-to-moderate COVID-19 in adults who have tested positive and are at high risk for progression to severe illness

0 196